Monte Rosa Therapeutics

Monte Rosa Therapeutics Founded in 2018, they use cutting-edge technology and disruptive strategies to reshape drug discovery and improve human health. The company’s research found that every cell has evolved complex mechanisms to regulate protein expression and function through degradation. This intricate mechanism involves controlling the ubiquitination of protein substrates via E3 ligase complexes. Using rationally designed small molecule degraders (also known as molecular glues), their goal is to hijack this natural process and redirect the degradation mechanism toward specific disease-causing proteins.